Boston, Massachusetts 2021-09-22 08:30:19 –
NSilead’s Covid-19 drug remdesivir appeared to reduce hospitalization for high-risk patients diagnosed early in the disease by 87% in a new study, the company said Wednesday.
The new results announced in the press release may help strengthen the perception that the drug is effective. They could also raise expectations for the use of oral antiviral drugs that pharmaceutical companies such as Pfizer and Merck are developing to treat people in the early stages of Covid-19.
Administration of remdesivir remains difficult. It must be given intravenously and was given in 3 infusions every 3 days in this study. This is a logistical hurdle for patients who are not hospitalized.
Remdesivir, under the Venklury brand name, is fully approved by the Food and Drug Administration for the treatment of Covid-19 and is widely used, but its effectiveness is still controversial. Studies conducted by Gilead and the National Institutes of Health have shown that it helps accelerate patient recovery. However, a second large study conducted by the World Health Organization did not show the drug’s benefits of reducing Covid mortality.
One challenge when using antiviral drugs like remdesivir is that they tend to work better in the early stages of the disease. Currently, remdesivir is an IV drug and is used to treat patients who are already in the hospital.
The purpose of this study was to test whether early administration of remdesivir could have a significant impact on Covid-19. However, Gilead stopped it in April 2021, when it registered only about half of the expected number of patients. According to the company, this is due to Covid-19’s “epidemiological changes” and “additional treatment options at the time,” with data on Regeneron and Eli Lilly monoclonal antibody cocktails that can be administered to outpatients with a single infusion. Means.
However, Gilead continued to analyze data from 562 patients who were enrolled in the study and were randomly assigned to receive either remdesivir or placebo. According to the company, hospitalizations have decreased by 87%. This means that 2 patients were hospitalized or died in the remdesivir group compared to 15 in the placebo group.
Covid-19 also reduced medical visits by 81%. (21 patients in the placebo group were hospitalized compared to 4 in the remdesivir group.)
Gilead said one person died in the placebo group in the study, but died after the 28-day cutoff in the main analysis.
The full results of the study will be presented at ID Week, a medical conference. Gilead did not immediately provide information on the demographics of the patients under study. According to the company, the side effects were similar to those seen in previous studies. The most common side effects were nausea and headache.
A Gilead spokesman said the company shared the results with the FDA.
Remdesivir reduces Covid hospitalizations when given early, study shows Source link Remdesivir reduces Covid hospitalizations when given early, study shows